Literature DB >> 26178291

Testicular orphan nuclear receptor 4 is associated with the radio-sensitivity of prostate cancer.

Shicheng Yu1, Mingchao Wang1, Xianfan Ding2, Liqun Xia1, Bide Chen1, Yicheng Chen1, Zhigen Zhang1, Yuanjie Niu3, Gonghui Li1, Chawnshang Chang2.   

Abstract

BACKGROUND: It is well known that a significant number of prostate cancers (PCa) showed different extents of radio-resistance and the tumor may recur after treatment. Recent studies demonstrated that Testicular orphan nuclear receptor 4 (TR4) could play a critical role in anti-oxidative stress responses and might modulate the DNA damage repair. The objective of this study is to investigate the role of TR4 in the radiotherapy for PCa.
METHODS: The TR4 expression in tissue samples from PCa patients treated with brachytherapy was measured by immunohistochemistry (IHC). Cell survival test and colony formation assay were applied to test the radio-sensitivity of PCa cells with modulated TR4 gene expression upon irradiation.
RESULTS: PCa patients with biochemical recurrence (BCR) after brachytherapy tend to have higher TR4 expression (80%, n = 30) as compared to those without BCR (36.67%, n = 30). Survival analysis demonstrated a significant higher BCR occurrence in patients with high level of TR4 expression (HR = 3.474, 95%CI 1.678-7.192, P = 0.0008). Multivariate analysis showed that the TR4 staining score on IHC was the only significant variable for predicting the PCa patients' clinical outcomes after radiotherapy (OR = 9.919, 95% CI 2.516-39.101, P = 0.001). Using cell survival test and colony forming assay, we found that the addition of functional TR4 in PC3 cells lead to elevated radio-resistance. In contrast, knocking-down TR4 in LNCaP cells resulted in increased radio-sensitivity. The γH2AX foci kinetic analysis suggested that knocking down TR4 might delay the PCa cell's DNA damage repair which would enhance the radio-sensitivity.
CONCLUSION: TR4 could mediate the PCa cells' radio-sensitivity and might become a prognostic indicator for PCa patients received radiotherapy. This study provides a novel approach to manipulate radio-sensitivity of PCa cells, and may bring a promoted therapeutic outcome of radiotherapy to battle PCa in future.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  prostate cancer; radio-sensitivity; radiotherapy; testicular orphan nuclear receptor 4

Mesh:

Substances:

Year:  2015        PMID: 26178291     DOI: 10.1002/pros.23044

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  6 in total

1.  Zerumbone Regulates DNA Repair Responding to Ionizing Radiation and Enhances Radiosensitivity of Human Prostatic Cancer Cells.

Authors:  Pai-Kai Chiang; Wei-Kung Tsai; Marcelo Chen; Wun-Rong Lin; Yung-Chiong Chow; Chih-Chiao Lee; Jong-Ming Hsu; Yu-Jen Chen
Journal:  Integr Cancer Ther       Date:  2017-06-12       Impact factor: 3.279

Review 2.  The Role of Nuclear Receptors in Prostate Cancer.

Authors:  Masaki Shiota; Naohiro Fujimoto; Eiji Kashiwagi; Masatoshi Eto
Journal:  Cells       Date:  2019-06-17       Impact factor: 6.600

3.  Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer.

Authors:  Jin Zhu; Peibo Qin; Cheng Cao; Guangcheng Dai; Lijun Xu; Dongrong Yang
Journal:  Oncol Rep       Date:  2021-01-05       Impact factor: 3.906

4.  Identification of Small-Molecule Regulators of Testicular Receptor 4 via a Drug Repurposing Screening.

Authors:  Liqun Xia; Danyang Shen; Huan Wang; Liangliang Ren; Yi Chen; Gonghui Li
Journal:  ACS Omega       Date:  2020-11-19

5.  Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.

Authors:  Hangchuan Shi; Yin Sun; Miao He; Xiong Yang; Michiaki Hamada; Tsukasa Fukunaga; Xiaoping Zhang; Chawnshang Chang
Journal:  Oncogene       Date:  2019-09-09       Impact factor: 9.867

6.  Atorvastatin Enhances Effects of Radiotherapy on Prostate Cancer Cells and Xenograft Tumor Mice Through Triggering Interaction Between Bcl-2 and MSH2.

Authors:  Zhenhua He; Jingmin Yuan; Fuhui Shen; Fangang Zeng; Ping Qi; Zhiping Wang; Zhenxing Zhai
Journal:  Med Sci Monit       Date:  2020-09-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.